Otsuka Pharma Day 2021

November 10, 2021 3:00 PM - 6:30 PM

MassBioHub, 700 Technology Square, 5th Floor Cambridge MA 02139

Add to Calendar 11/10/2021 3:00:00 PM 11/10/2021 6:30:00 PM Otsuka Pharma Day 2021

Otsuka America Pharmaceutical, Inc., invites biotech and digital health companies to join them on November 10 and 11 for an information session, networking reception, and one-on-one meetings to discuss potential collaboration opportunities.

Otsuka and its affiliated companies Visterra and the McQuade Center for Strategic Research and Development (MSRD), are interested in meeting with companies with investigational therapeutic programs in the areas of neuroscience, nephrology, autoimmune diseases and digital innovation.

Please note: MassBio is taking all appropriate precautions while also closely monitoring the latest public health guidance. Accordingly, all attendees for this event are required to be fully vaccinated. Additionally, Otsuka will provide onsite rapid testing and masks will be required in all common areas of the event space. 

Discover | Join Otsuka’s open information session and networking reception on November 10 at 3:00 p.m. ET for an overview of its R&D strategy, target therapeutic areas, clinical development expertise and commercial capabilities. Note: Upon registration, your registration status will say "Pending Approval." This triggers the system to send you a confirmation email within 1-3 business days.


3:00 – 3:30pm       Registration & Networking
3:30 – 3:50pm       Opening Remarks & Otsuka Overview
                                    Kendalle Burlin O’Connell, President & COO, MassBio
                                    Kabir Nath, President & CEO, OAPI†

3:50 – 4:30pm       Otsuka: Your Best Choice

  • Bringing New Drugs to Patients
    John Kraus, VP Global Clinical Development, CNS, OPDC†
  • Creating Value through Collaboration
    Zach Shriver, CSO, Visterra†
  • At the Forefront of Science and Innovation
    Nathan Styles, Sr. Director, MSRD†

4:30 – 4:45pm       Panel Discussion: Working with Otsuka
                                   Kabir Nath, President & CEO, OAI†
                                   John Kraus, VP Global Clinical Development, CNS, OPDC†
                                   Zach Shriver, CSO, Visterra†
                                   Nathan Styles, Sr. Director, MSRD†
                                   Haru Sugino, Sr. Director, Business Development, OPDC†
                                   Sahil Kirpekar, Head of Business Development, OAPI†
                                   Moderator: Armin Rump, Assoc. Director, Business Development, OPDC†
4:45 – 5:00pm    Q&A and Closing Remarks
5:00 – 6:30pm    Networking Reception

Otsuka Attendees


  • Kabir Nath, Sr. Managing Director Global Pharmaceutical Business, OPC† and President & CEO, OAPI†
  • John Kraus, VP Global Clinical Development, CNS, OPDC†
  • Zach Shriver, CSO, Visterra†
  • Jonathan Zombeck, Assoc. Director, Strategic Alliances & Business Development, Visterra†
  • Nathan Styles, Sr. Director, MSRD†
  • Nicole Meade, Assoc. Director, Strategic Research & Development, MSRD†
  • Haruhiko Sugino, Sr. Director, Business Development, OPDC†
  • Armin Rump, Assoc. Director, Business Development, OPDC†
  • Yasuro Iwasaki, Sr. Manager, Business Development, OPDC†
  • Hiroshi Ikeuchi, Sr. Manager, Business Development, OPDC†
  • Sahil Kirpekar, Head of Business Development, OAPI†
  • Praveen Kundithipudi, Director, Business Development, OAPI†
  • Zhen Fang Huang Cao, Assoc. Director, Business Development, OAPI†
  • Andre Bechuate, Business Development Project Management, OAPI†
  • Jeffrey Weness, Head of Digital Opportunities and Business Intelligence, OAPI†
  • Ethan Wergelis-Isaacson, Assoc. Director, Search & Evaluation, Digital Health, OAPI†
  • Takeshi Watanabe, Head of Evaluation, Business Development, OPC† (remote)
  • Koji Ogata, Sr. Director, Business Development, OPC† (remote)
  • Shinji Sato, Director, Business Development, OPC† (remote)
  • Keisuke Nagano, Director, Scientific Evaluation, OPC† (remote)
  • Bruce Leslie, Sr. Director, Global Clinical Development, OPDC† (remote)
  • Olga Krylova, Director, Business Development, OPEL† (remote)

*Attendees and Agenda Subject to Change.  Remote participants will join select meetings by video.
†OPDC (Otsuka Pharmaceutical Development & Commercialization, Inc.), OAPI (Otsuka America Pharmaceutical, Inc.), OAI (Otsuka America, Inc.), OPEL (Otsuka Pharmaceutical Europe Ltd.), MSRD (McQuade Center for Strategic Research & Development) and Visterra, Inc. are affiliates of OPC (Otsuka Pharmaceutical Co., Ltd.), which is a subsidiary of Otsuka Holdings, a public company listed on the Tokyo Stock Exchange.

About Otsuka
Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: “Otsuka–people creating new products for better health worldwide.” In the U.S., Otsuka is comprised of two companies, Otsuka America Pharmaceutical, Inc., and Otsuka Pharmaceutical Development & Commercialization, Inc., that share a deep commitment to the development and commercialization of innovative products in the spaces of neuroscience, nephrology, and digital medicine.

Driven by our purpose to defy limitation, so that others can too, we have an unwavering belief in doing more and transcending expectations. In going above and beyond—under any circumstances—for patients, families, providers, and for each other. It’s this deep-rooted dedication that drives us to uncover answers to complex, underserved medical needs, so that patients can push past the limitations of their disease and achieve more than they thought was possible each and every day. OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Company, Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd., founded in 1921 and headquartered in Tokyo, Japan. The Otsuka group of companies employed 47,000 people worldwide and had consolidated sales of approximately USD 13.3 billion in 2020.

Otsuka’s product portfolio includes ABILIFY® (aripiprazole), ABILIFY MAINTENA® (aripiprazole) for extended release injectable suspension, REXULTI® (brexpiprazole), and JYNARQUE® (tolvaptan).

For comprehensive information about Otsuka, please visit

About Visterra
Visterra is a clinical stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. Its proprietary Hierotope® platform enables the design and engineering of precision antibody-based product candidates that specifically bind to, and modulate, key disease targets that are not adequately addressed by traditional therapeutic approaches. The platform also includes Fc engineering capabilities for half-life extension, bispecific antibodies and antibody-drug conjugates (ADCs). Visterra is a wholly-owned subsidiary of Otsuka America, Inc., a holding company and wholly-owned subsidiary of Otsuka Pharmaceutical Co. Ltd. Of Japan. For more information, please visit

About MSRD
The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, was established in 2019 by the Otsuka US Pharmaceutical Business to search for, identify and fund innovative early-stage research/development programs that have the potential to build the future portfolio of Otsuka products. MSRD’s three-pronged approach entails discovery of early stage, creative assets and programs, establishment of open communication and agile collaboration, ultimately delivering upon investments in novel treatments that address unmet medical needs. For more information, please visit

MassBioHub, 700 Technology Square, 5th Floor Cambridge MA 02139